1. Home
  2. BPMC
  3. BPMC News

Latest Blueprint Medicines Corporation (BPMC) News on April 2, 2025

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
BPMC

PR Newswire

2 days ago

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy?
BPMC

Insider Monkey

3 days ago

Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy?

Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts
BPMC

Insider Monkey

7 days ago

Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts

Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March
BPMC

Insider Monkey

13 days ago

Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls
BPMC

TipRanks

15 days ago

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

BPMC

MT Newswires

15 days ago

Wolfe Research Initiates Blueprint Medicines at Outperform With $132 Price Target

Exploring High Growth Tech Stocks In The US Market March 2025
BPMC

Simply Wall St.

20 days ago

Exploring High Growth Tech Stocks In The US Market March 2025

BPMC

MT Newswires

a month ago

Blueprint Medicines Insider Sold Shares Worth $467,266, According to a Recent SEC Filing

BPMC

MT Newswires

a month ago

Blueprint Medicines Insider Sold Shares Worth $576,223, According to a Recent SEC Filing

BPMC

MT Newswires

a month ago

Blueprint Medicines Insider Sold Shares Worth $576,756, According to a Recent SEC Filing

BPMC

MT Newswires

a month ago

Blueprint Medicines Insider Sold Shares Worth $1,434,209, According to a Recent SEC Filing

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
BPMC

PR Newswire

a month ago

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now
BPMC

Insider Monkey

a month ago

Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now

Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations
BPMC

Simply Wall St.

2 months ago

Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
BPMC

Zacks

2 months ago

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...
BPMC

GuruFocus.com

2 months ago

Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...

BPMC

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Blueprint Medicines Corp Earnings Call

BPMC

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Blueprint Medicines to $128 From $124, Maintains Outperform Rating

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
BPMC

Zacks

2 months ago

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

BPMC

MT Newswires

2 months ago

Blueprint Medicines Q4 Loss Narrows, Revenue Rises

BPMC

Associated Press Finance

2 months ago

Blueprint Medicines: Q4 Earnings Snapshot

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
BPMC

PR Newswire

2 months ago

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
BPMC

Zacks

2 months ago

Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know
BPMC

Zacks

2 months ago

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
BPMC

Zacks

2 months ago

Should You Buy Blueprint Medicines (BPMC) After Golden Cross?

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
BPMC

PR Newswire

2 months ago

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Why Blueprint Medical (BPMC) Is Skyrocketing Now
BPMC

Insider Monkey

2 months ago

Why Blueprint Medical (BPMC) Is Skyrocketing Now

BPMC

MT Newswires

2 months ago

Blueprint Medicines Insider Sold Shares Worth $1,660,511, According to a Recent SEC Filing

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
BPMC

Zacks

3 months ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
BPMC

Zacks

3 months ago

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

5 Biotech Stocks Worth Adding to Your Portfolio in 2025
BPMC

Zacks

3 months ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
BPMC

Zacks

3 months ago

Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?

BPMC

MT Newswires

3 months ago

Blueprint Medicines Expects Systemic Mastocytosis Franchise to Generate $4 Billion by 2030 -- Shares Up

Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor
BPMC

GuruFocus.com

3 months ago

Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
BPMC

PR Newswire

3 months ago

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

High Growth Tech Stocks to Watch in January 2025
BPMC

Simply Wall St.

3 months ago

High Growth Tech Stocks to Watch in January 2025

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BPMC

PR Newswire

3 months ago

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
BPMC

PR Newswire

4 months ago

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Exploring Three High Growth Tech Stocks in the United States
BPMC

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks in the United States

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
BPMC

Zacks

4 months ago

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?

BPMC

MT Newswires

4 months ago

Blueprint Medicines Insider Sold Shares Worth $1,869,658, According to a Recent SEC Filing

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
BPMC

Benzinga

5 months ago

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

BPMC

MT Newswires

5 months ago

JPMorgan Initiates Blueprint Medicines at Overweight With $126 Price Target

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report
BPMC

Simply Wall St.

5 months ago

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report

High Growth Tech Stocks to Watch in November 2024
BPMC

Simply Wall St.

5 months ago

High Growth Tech Stocks to Watch in November 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations
BPMC

Simply Wall St.

5 months ago

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
BPMC

Zacks

5 months ago

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...
BPMC

GuruFocus.com

5 months ago

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...

BPMC

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Blueprint Medicines Corp Earnings Call

BPMC

MT Newswires

5 months ago

Wedbush Adjusts Price Target on Blueprint Medicines to $135 From $129, Maintains Outperform Rating

BPMC

MT Newswires

5 months ago

Blueprint Medicines Q3 Loss Narrows, Revenue Increases; 2024 Product Sales Guidance Lifted

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
BPMC

Zacks

5 months ago

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

BPMC

Associated Press Finance

5 months ago

Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
BPMC

PR Newswire

5 months ago

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic?
BPMC

Simply Wall St.

5 months ago

Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic?

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
BPMC

Zacks

5 months ago

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

BPMC

MT Newswires

5 months ago

UBS Initiates Blueprint Medicines at Neutral With $88 Price Target

Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
BPMC

Zacks

5 months ago

Regeneron (REGN) Earnings Expected to Grow: Should You Buy?

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BPMC

Zacks

5 months ago

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
BPMC

Zacks

5 months ago

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
BPMC

PR Newswire

6 months ago

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know
BPMC

Zacks

6 months ago

Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know

BPMC

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 10/07/2024

BPMC

MT Newswires

6 months ago

Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
BPMC

Zacks

7 months ago

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?

High Growth Tech Stocks To Watch In September 2024
BPMC

Simply Wall St.

7 months ago

High Growth Tech Stocks To Watch In September 2024

Blueprint Medicines to Present at Upcoming Investor Conferences
BPMC

PR Newswire

7 months ago

Blueprint Medicines to Present at Upcoming Investor Conferences

Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
BPMC

Zacks

7 months ago

Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?

Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)
BPMC

GuruFocus.com

7 months ago

Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)

Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
BPMC

Zacks

8 months ago

Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

BPMC

MT Newswires

8 months ago

Blueprint Medicines Insider Sold Shares Worth $3,905,872, According to a Recent SEC Filing

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up
BPMC

Zacks

8 months ago

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up

Analysts Just Shipped A Sizeable Upgrade To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
BPMC

Simply Wall St.

8 months ago

Analysts Just Shipped A Sizeable Upgrade To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines Second Quarter 2024 Earnings: Beats Expectations
BPMC

Simply Wall St.

8 months ago

Blueprint Medicines Second Quarter 2024 Earnings: Beats Expectations

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
BPMC

Zacks

8 months ago

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat

BPMC

MT Newswires

8 months ago

Wedbush Adjusts Blueprint Medicines' Price Target to $129 From $120, Keeps Outperform Rating

BPMC

MT Newswires

8 months ago

Blueprint Medicines Q2 Loss Narrows, Revenue Rises

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
BPMC

Zacks

8 months ago

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

BPMC

Associated Press Finance

8 months ago

Blueprint Medicines: Q2 Earnings Snapshot

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
BPMC

PR Newswire

8 months ago

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
BPMC

Zacks

8 months ago

Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
BPMC

Zacks

8 months ago

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
BPMC

PR Newswire

8 months ago

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

BPMC

MT Newswires

9 months ago

Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating

BPMC

MT Newswires

9 months ago

Blueprint Medicines Insider Sold Shares Worth $7,713,537, According to a Recent SEC Filing

How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'
BPMC

Investor's Business Daily

9 months ago

How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'

Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
BPMC

GuruFocus.com

10 months ago

Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)

BPMC

MT Newswires

10 months ago

Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing

Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares
BPMC

GuruFocus.com

10 months ago

Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares

BPMC

MT Newswires

10 months ago

Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing

BPMC

MT Newswires

10 months ago

Blueprint Medicines Insider Sold Shares Worth $4,136,328, According to a Recent SEC Filing

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
BPMC

PR Newswire

10 months ago

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

BPMC

MT Newswires

10 months ago

Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
BPMC

PR Newswire

10 months ago

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year
BPMC

Simply Wall St.

10 months ago

Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year

BPMC

MT Newswires

a year ago

Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BPMC

Zacks

a year ago

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand

BPMC

MT Newswires

a year ago

Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BPMC

PR Newswire

a year ago

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BPMC

MT Newswires

a year ago

Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating

Share on Social Networks: